OR WAIT null SECS
© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.
April 1st 2021
Dr. Rebecca Previs reviews first line treatment options for patients with advanced ovarian cancer.
An expert in gynecologic oncology talks about the role of bevacizumab in the front-line management of advanced ovarian cancer.
April 8th 2021
Dr. Rebecca Previs explains the importance of somatic and germline testing in guiding first line treatment selection in women with advanced ovarian cancer.
An expert oncologist reviews therapeutic options for front line maintenance in advanced ovarian cancer.
April 15th 2021
Dr. Rebecca Previs discusses the role of PARP inhibitors in first line maintenance therapy in advanced ovarian cancer.
Dr. Rebecca Previs talks about when first line maintenance therapy is appropriate and which patients should be presented with this option.
April 22nd 2021
An expert in ovarian cancer describes how initial first line therapy impacts first line maintenance options.
Dr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer.
This article reviews emerging evidence on PARP inhibitors as first-line maintenance treatment options after chemotherapy and features expert insights from Rebecca Previs, MD.